Zoetis Reaffirms Full-Year Guidance at Morgan Stanley Healthcare Conference

NEW YORK — Executive leadership at Zoetis Inc. (NYSE: ZTS) reaffirmed the company’s revised operational revenue guidance at the Morgan Stanley 24th Annual Global Healthcare Conference, demonstrating financial resilience despite facing a post-pandemic normalization slump in U.S. companion animal care and rising competitive pressures.

Speaking at the fireside presentation, Chief Executive Officer Kristin Peck and incoming CFO/COO Jay Saccaro addressed market concerns regarding softer clinic traffic, pricing dynamics, and multi-front competition.

Key Financial Guidance & Conference Takeaways

• Operational Revenue Guidance Reaffirmed: Zoetis confirmed its operational revenue expectation of −3% to −1%.

• U.S. Vet Visit Normalization: Wellness and preventative clinic visits in the U.S. continue to soften as pet ownership normalizes following pandemic highs. However, urgent, acute, and critical care segments remain resilient.

• Defending Market Share Over Margins: Management highlighted a strategic pivot toward targeted promotional investments and customer retention to protect core market share in dermatology and parasiticides, choosing share defense over aggressive short-term margin expansion.

• Stable Base Pricing: CEO Kristin Peck emphasized that current headwinds are cyclical rather than structural. The company has resisted broad list price cuts, relying instead on time-limited promotions and direct-to-consumer digital channels.

Navigating U.S. Pet-Care Headwinds & Competitive Pressures

The animal health giant is confronting a multi-category competitive environment:

1. Dermatology Arena: Entrenched offerings like Apoquel® and Cytopoint® face heightened competition from new market entrants including Elanco Animal Health and Merck Animal Health.

2. Parasiticide Rivalry: Zoetis’s triple-combination oral parasiticide Simparica Trio® is defending market share against rival products, such as Elanco’s Credelio® line and Merck’s NexGard® family.

3. Distribution Shift: While traditional foot-traffic visits to veterinary clinics have contracted, direct-to-consumer, e-commerce, and home delivery sub-channels continue to generate double-digit growth.

Long-Term Growth Drivers & Pipeline Catalysts

Despite near-term top-line friction, management outlined key operational catalysts positioning the business for a long-term rebound:

• Chronic Kidney Disease (CKD) Pipeline: Management identified its upcoming $3 Billion addressable market opportunity in CKD as its primary near-term biological innovation, targeting initial regulatory approvals to slow disease progression in felines and canines.

• Livestock Segment Offset: The livestock sector continues to exceed historical baselines with mid-to-double-digit growth, bolstered by expanding global protein production and protein consumption trends in developed markets.

• M&A and Emerging Markets Expansion: Zoetis is continuing targeted capital allocation toward emerging market expansion and external innovation pipelines to sustain long-term enterprise value.

Wall Street & Analyst Outlook

Equity analysts note that Zoetis’s strategy reflects a pragmatic defense of its market-leading franchises. By refusing to engage in price wars while leaning into targeted commercial promotions and R&D-driven product pipelines (such as long-acting injectables and renal therapies), Zoetis aims to navigate the current cyclical trough and emerge with intact customer relationships as clinic visit volumes stabilize.